Event Details
Sachs 7th Annual Immuno-Oncology Innovation Forum
May 18 2021
The Sachs 7th Annual Immuno-Oncology innovation forum for business development, licensing and investment will take place from 18th to 20th May as a digital conference.
The programme will be spread across 3 days bringing together leaders from pharma and biotech as well as cancer research institutes, patient advocacy groups and late stage investors.
The event brings together over 300 delegates with more than 25 company presentations. Over half of the attendees are corporate and financial investors, buy-side and sell-side analysts, bankers, legal and business advisors.
Our Business Development team is looking forward to meeting with partners who are interested to find out more about our work. We are available to schedule a meeting at your convenience at the Partnering Lounge during the conference or via email at BD@nanobiotix.com.
Management from Nanobiotix will speak at the following sessions:
Agenda
Pharma-Bio DealMaking: M&A and Partnering Panel
Tuesday, 18 May, 11.30 am EDT
Panelist from Nanobiotix: Patrick Tricoli, CEO of Nanobiotix USA & EVP, Global Head of BD, Nanobiotix Corp.
Co-Chaired by: Michael Kingston, Managing Director & Co-Head of North America Life Sciences, Lazard Ltd. and Peter Sandor, SVP, PFL Oncology, Astellas Pharma, Inc.
Fireside Chat
Tuesday, 18 May, 12.50 pm EDT
Keynote speaker: Patrick Tricoli, CEO of Nanobiotix USA & EVP, Global Head of BD, Nanobiotix Corp.
Moderated by: Jeffrey Bockman, EVP, Head of Oncology Practice, Cello Health BioConsulting
This session will be focused on opportunities in the enhancement of radiotherapy with immunotherapy.
Development Strategies for Current Times Panel
Tuesday, 18 May, 1.10 pm EDT
Panelist from Nanobiotix: Scott Wieland, Executive Vice President, Development, Nanobiotix Corp
Co-Chaired by: Esteban Pombo-Villar, CEO, TargImmune Therapeutics AG and Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA.